The QALY: How do we make it more meaningful?
The recent viewpoint by Neumann and Cohen offers a balanced discussion around the controversial quality-adjusted…
Pharmaceutical Market Strategies
The recent viewpoint by Neumann and Cohen offers a balanced discussion around the controversial quality-adjusted…
With the news of the White House’s Council of Economic Advisors (CEA) report to address…
This has been on my mind since last Thursday after an advisor to my research…
The folks at Health Affairs released a themed issue this month on Pursuing Health Equity,…
As with the long delay between epic Star Wars films, our Drug Price Wars series…
There have been some great posts recently along with a working paper from the National…
Recently, President Donald Trump met with executives from the Pharmaceutical Research and Manufacturers of America…
A guest post by Mike Paulden, Health Economist from the University of Alberta, and Dr.…
I recently had the opportunity to work with a couple amazing economists on a little…